"Today, Maryland Oncology Hematology is the largest independent Medical Oncology and Hematology group in Maryland with 30 physicians practicing in 9 locations across central Maryland. Dedicated to providing the most advanced cancer care available anywhere in an atmosphere of caring compassion."

During the past decade, Oncology-Hematology Associates, P.A. conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 1 clinical trials were completed, i.e. on average, 12.5% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Oncology-Hematology Associates, P.A." #1 sponsor was "Novartis Pharmaceuticals" with 2 trials, followed by "Pharmatech Oncology" with 2 trials sponsored, "Accelerated Community Oncology Research Network" with 1 trials sponsored, "Agendia" with 1 trials sponsored and "Calithera Biosciences, Inc" with 1 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Oncology-Hematology Associates, P.A." #1 collaborator was "Millennium Pharmaceuticals, Inc." with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Oncology-Hematology Associates, P.A." are "Breast Cancer" (3 trials), "Multiple Myeloma" (3 trials), "Non-Small Cell Lung Cancer" (2 trials), "Advanced Breast Cancer" (1 trials) and "Breast Neoplasm" (1 trials). Many other conditions were trialed in "Oncology-Hematology Associates, P.A." in a lesser frequency.

Most popular intervention types in "Oncology-Hematology Associates, P.A." are "Drug" (12 trials), "Biological" (2 trials), "Diagnostic Test" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "gemcitabine hydrochloride" (2 trials), "zoledronic acid" (2 trials), "Abemaciclib" (1 trials) and "Bortezomib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Oncology-Hematology Associates, P.A." are 16 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Oncology-Hematology Associates, P.A.". undefined are not yet recruiting, 3 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Oncology-Hematology Associates, P.A., undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Oncology-Hematology Associates, P.A., 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".